1. Home
  2. BLBD vs SNDX Comparison

BLBD vs SNDX Comparison

Compare BLBD & SNDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Blue Bird Corporation

BLBD

Blue Bird Corporation

N/A

Current Price

$56.27

Market Cap

1.9B

ML Signal

N/A

Logo Syndax Pharmaceuticals Inc.

SNDX

Syndax Pharmaceuticals Inc.

N/A

Current Price

$16.95

Market Cap

1.6B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
BLBD
SNDX
Founded
1927
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Construction/Ag Equipment/Trucks
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.9B
1.6B
IPO Year
2013
2014

Fundamental Metrics

Financial Performance
Metric
BLBD
SNDX
Price
$56.27
$16.95
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
8
12
Target Price
★ $89.13
$37.55
AVG Volume (30 Days)
445.5K
★ 1.6M
Earning Date
11-23-2026
11-02-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 22.78
11.56
EPS
★ 7.33
N/A
Revenue
★ $1,480,099,000.00
$172,352,000.00
Revenue This Year
$18.37
$82.71
Revenue Next Year
$14.95
$45.79
P/E Ratio
$7.67
★ N/A
Revenue Growth
9.87
★ 627.84
52 Week Low
$46.14
$13.00
52 Week High
$83.39
$25.59

Technical Indicators

Market Signals
Indicator
BLBD
SNDX
Relative Strength Index (RSI) 38.82 36.00
Support Level $53.46 N/A
Resistance Level $64.17 $18.75
Average True Range (ATR) 1.71 0.75
MACD 0.15 -0.06
Stochastic Oscillator 31.03 19.22

Price Performance

Historical Comparison
BLBD
SNDX

About BLBD Blue Bird Corporation

Blue Bird Corp is an American bus manufacturing company. It is an independent designer and manufacturer of school buses. The company operates in two segments; the Bus segment which involves the design, engineering, manufacture, and sales of school buses and extended warranties; and the Parts segment which includes the sales of replacement bus parts. Geographically, the company generates a majority of its revenue from its customers in the United States and the rest from Canada and Rest of the world.

About SNDX Syndax Pharmaceuticals Inc.

Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.

Share on Social Networks: